Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

March 12, 2007 10:00 ET

Stem Cell Therapeutics Corp. to Present at the Sachs Associates 6th Annual North American Investing & Partnering Forum

CALGARY, ALBERTA--(CCNMatthews - March 12, 2007) -

This release is intended for distribution in Canada only and is not to be distributed to United States newswire services or disseminated in the United States

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") announced today that Dr. Alan Moore, President and CEO, will present at the Sachs Associates North America Forum to be held at the Fairmont Copley Plaza in Boston, MA.

Dr. Moore's presentation will provide a corporate summary and include an overview of SCT's currently enrolling Phase IIa clinical safety study administering NTx™-265 to stroke patients. This important forum is attended by industry executives, potential collaborators, investors and members of the financial community.

About Sachs Associates North America Forum: ( ):
The 6th Annual North America Forum for Investing & Partnering in Biotech is a high profile event attended by an executive level audience of investors, pharmaceutical company representatives, fund managers and capital raising companies. The event provides prime executive level networking and deal making opportunities. Highly regarded for successfully bringing together both early- to mid-stage growth companies and venture capital investors as well as a growing number of mid cap venture growth backed companies, the 2007 programme will include roundtables on key industry and scientific developments as well as finance and investment trends and keynote presentations from leading investment, pharmaceutical and biotech companies.

About NTx™-265: NTx™-265 is a therapeutic regimen of two drugs being developed by SCT for the treatment of stroke. Human chorionic gonadotropin (hCG) is the first drug administered in the regimen, and aims to increase the number of neural stem cells (NSCs) located in the brain of a patient suffering from a recent stroke. Erythropoietin (EPO) is the second drug administered in the regimen, and aims to promote the differentiation of these newly formed NSCs into new neurons. New neurons thus formed are anticipated to provide benefit to the patient through the replacement of the brain cells that were lost or damaged by the stroke. Animal studies have shown a significant recovery in motor function in animals that have been given a stroke and subsequently been treated with the NTx™-265 therapy. Currently, SCT is enrolling patients in a phase IIa clinical trial in the United States in order to investigate the safety and efficacy of NTx™-265 in humans.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. SCT's currently enrolling phase IIa clinical program for NTx™-265 targets the treatment of stroke by repurposing approved and clinically well defined drugs. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information